STOCK TITAN

Zomedica Corp - ZOM STOCK NEWS

Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.

Overview

Zomedica Corp (NYSE American: ZOM) is an innovative veterinary healthcare company dedicated to enhancing animal health through advanced diagnostic and therapeutic solutions. Specializing in point-of-care technologies for companion animals and equines, the company offers a robust portfolio designed to address the unmet needs of clinical veterinarians and improve practice efficiencies. With a focus on novel diagnostic platforms and non-invasive therapeutic devices, Zomedica empowers veterinary professionals to lower operating costs, increase productivity, and ultimately deliver superior patient care.

Product Portfolio and Technological Innovations

Zomedica's offerings include an array of cutting-edge products that integrate advanced imaging, automated diagnostic capabilities, and innovative therapeutic modalities. The company is renowned for its TRUFORMA diagnostic platform, a system that utilizes proprietary sensor technologies for accurate and rapid testing. Alongside this, its digital cytology system and remote monitoring solutions enhance the precision of diagnoses and clinical decision-making. Additionally, Zomedica’s novel therapeutic devices are designed to accelerate healing processes and minimize patient discomfort through non-invasive methods.

Market Position and Competitive Edge

Operating within the broader veterinary health industry, Zomedica has established a strong market position by addressing both clinical and business challenges faced by veterinarians. The company differentiates itself with a deep commitment to research and development, leveraging the insights of practicing veterinary professionals to tailor its product suite. This focus on innovation has allowed Zomedica to not only meet the growing demand for efficient, point-of-care diagnostic tools but also to set new operational standards across veterinary practices. Its comprehensive solutions enable veterinarians to conduct tests quickly and accurately, thereby reducing turnaround times and enhancing patient care.

Operational Excellence and Global Reach

Headquartered in Michigan, Zomedica operates from world-class manufacturing and distribution facilities that underscore its commitment to quality and efficiency. With manufacturing operations in key U.S. regions, the company ensures consistent delivery of high-quality products to its domestic and international markets. Zomedica's strategic partnerships in various regions further complement its mission of expanding access to advanced veterinary care globally. The company’s investments in cleanroom technologies and automated production lines not only enhance manufacturing capacity but also streamline logistics and distribution processes.

Benefits to Veterinary Practices

The integrated solutions offered by Zomedica are specifically designed to improve the workflow and profitability of veterinary practices. By automating complex diagnostic procedures and providing rapid, lab-quality results at the point of care, the company enables veterinarians to focus on delivering improved patient outcomes. Enhanced diagnostic speed, reduced operational costs, and increased efficiency are key factors driving the widespread adoption of Zomedica’s technologies in veterinary clinics across varied market segments.

Commitment to Innovation and Quality Care

Underpinned by the insights of industry experts and built on robust scientific research, Zomedica remains committed to continuous improvement in veterinary care. The company’s strategic focus on innovation, combined with its rigorous quality control measures, supports a wide spectrum of diagnostic and therapeutic applications. This dedication not only bolsters the confidence of veterinary professionals in adopting its technologies but also reinforces the company’s reputation for excellence, expertise, and trustworthiness in the veterinary healthcare industry.

Conclusion

Zomedica Corp stands out as a pioneering force in the veterinary health sector by delivering comprehensive, technology-driven solutions that enhance both clinical outcomes and practice management. Through its innovative product portfolio and strategic operational excellence, Zomedica continues to influence the evolution of veterinary diagnostics and therapeutics, enabling veterinarians to provide top-tier care to companion and equine patients.

Rhea-AI Summary

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has partnered with Qorvo Biotechnologies to develop three canine diagnostic assays for gastrointestinal issues: Cobalamin, cPL, and Folate. This initiative triggers a $2 million milestone payment under their agreement. These assays will enhance the TRUFORMA platform, enabling veterinarians to perform comprehensive gastrointestinal testing at the point-of-care, potentially improving diagnosis and treatment speed. The BAW sensor technology used in TRUFORMA promises laboratory-level accuracy, addressing a significant market need as GI conditions are common pet insurance claims.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
none
-
Rhea-AI Summary

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) shares updates on its lead product, TRUFORMA, in a letter from Interim CEO Robert Cohen. With over US $50 million in cash, Zomedica aims to launch TRUFORMA with five assays, verified in partnership with Qorvo. The letter emphasizes rigorous validation and testing processes, and a hybrid sales model involving regional distributors and direct sales staff. Shareholder approval for a proposed reverse stock split is sought to comply with NYSE American requirements. Cohen expresses optimism about the company's future amidst ongoing challenges, including COVID-related adjustments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) reported its second quarter financial results for the period ending June 30, 2020. The company posted a net loss of $5.3 million ($0.02 per share), an increase from $2.4 million in the same quarter last year. Research and development expenses surged 268%, totaling $3.9 million due to a milestone expense. However, cash reserves improved to $29.1 million from $510,586 at the end of 2019, aided by several equity offerings totaling $54 million. Zomedica aims to enhance its TRUFORMA™ diagnostic platform with ongoing validations and strong partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
Rhea-AI Summary

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced the appointment of Robert Cohen as a member of the Board of Directors, alongside Christopher Wolfenberg from Fasken Martineau DuMoulin LLP. Cohen joined Zomedica in June 2020, bringing over 20 years of experience in medical devices and biotechnology. The company is preparing for its Annual and Special Virtual-Only Meeting on September 25, 2020, where shareholders will ratify amendments to the by-laws facilitating electronic meetings and voting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
management
-
News
Rhea-AI Summary

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced the resignation of Shameze Rampertab as Chief Financial Officer, effective August 14, 2020. Ann Cotter, CPA, currently the Vice President of Finance, will serve as interim CFO. Cotter has extensive experience in accounting and finance, having worked in various roles since August 2018. CEO Robert Cohen expressed gratitude for Rampertab's four years of service and looks forward to working with Cotter as the company prepares for the commercial release of its TRUFORMA™ platform, aimed at addressing unmet needs in veterinary diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
-
Rhea-AI Summary

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has successfully implemented the first remote installations of its TRUFORMA™ diagnostic device, facilitating validation testing with partner universities despite COVID-19 challenges. The device, designed for veterinary point-of-care diagnostics, recently completed verification for canine cortisol testing and plans to add more assays. Interim CEO Robert Cohen emphasizes the company's commitment to bringing TRUFORMA to market promptly, highlighting its innovative technology and the dedication of its team.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.5%
Tags
none
Rhea-AI Summary

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has priced a public offering of 187.5 million common shares and short-term warrants at $0.16 each, targeting approximately $30 million in gross proceeds. The offering is expected to close around July 7, 2020, pending customary conditions. Funds will primarily support the development of the TRUFORMA™ diagnostic platform and may also be used for potential repurchases of Series 1 Preferred Shares. H.C. Wainwright & Co. is the placement agent. The offering is not available to Canadian residents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.33%
Tags
-
Rhea-AI Summary

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has announced a public offering of its common shares and warrants, all to be sold by the company. The offering is subject to market conditions, and its specific terms, including size and completion timing, are not guaranteed. Proceeds will primarily support development of the TRUFORMA™ diagnostic platform, including milestone payments under existing agreements and general corporate needs. H.C. Wainwright & Co. is the exclusive placement agent. The offering will not be available to Canadian residents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.33%
Tags
-
Rhea-AI Summary

Zomedica Pharmaceuticals Corp. has appointed Robert Cohen as its new Interim Chief Executive Officer, effective immediately. Cohen brings over 15 years of experience in the medical device and biotech industries, including a proven track record in launching medical devices. He will lead the completion and commercial launch of Zomedica's TRUFORMA™ diagnostic platform. Former interim CEO, Shameze Rampertab, remains as Chief Financial Officer. The company has raised over $30 million under Rampertab's leadership, supporting its development and commercialization efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.79%
Tags
management
Rhea-AI Summary

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced a public offering of 133.3 million common shares and warrants at $0.15 each, aiming to raise approximately $20 million before expenses. The offering is set to close around May 29, 2020, and is managed by H.C. Wainwright & Co. Funds will be used for the development of Zomedica's TRUFORMA™ diagnostic platform and other general corporate purposes. The offering is detailed under SEC registration statement File No. 333-238322, and the securities are not available to Canadian residents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.75%
Tags

FAQ

What is the current stock price of Zomedica (ZOM)?

The current stock price of Zomedica (ZOM) is $0.0973 as of March 5, 2025.

What is the market cap of Zomedica (ZOM)?

The market cap of Zomedica (ZOM) is approximately 95.3M.

What is the core business of Zomedica Corp?

Zomedica Corp focuses on providing innovative diagnostic and therapeutic solutions for veterinary applications, enhancing care for companion and equine animals.

Which markets does Zomedica serve?

The company serves the veterinary healthcare market with products used in both companion animal and equine practices across domestic and international regions.

What type of products does Zomedica offer?

Zomedica offers a range of point-of-care diagnostic platforms, imaging systems, and therapeutic devices designed to streamline practice workflows and improve patient outcomes.

How does Zomedica differentiate itself in the veterinary industry?

By integrating advanced technology with clinically-driven insights, Zomedica delivers precise, rapid diagnostic results and innovative therapeutic solutions that address critical unmet needs in veterinary practices.

What role does the TRUFORMA diagnostic platform play in their offerings?

The TRUFORMA platform provides automated, high-precision diagnostic capabilities at the point of care, reducing turnaround times and enhancing the accuracy of veterinary diagnostics.

How does Zomedica improve operational efficiencies for veterinary clinics?

Their innovative products automate complex diagnostic processes and streamline clinical workflows, leading to faster decision-making, lower costs, and improved patient care.

Why is Zomedica considered an expert in veterinary healthcare?

The company’s commitment to R&D, its science-backed product innovations, and strategic partnerships with veterinary professionals collectively reinforce its reputation for expertise and trustworthiness in the industry.
Zomedica Corp

NYSE:ZOM

ZOM Rankings

ZOM Stock Data

95.35M
961.51M
1.87%
9.37%
4.63%
Medical Devices
Pharmaceutical Preparations
Link
United States
ANN ARBOR